Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics Inc. Director Gillian Cannon was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director Joshua M. Murray was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director James N. Wilson was granted 25,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director Kimberly Park was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

A director at Corcept Therapeutics exercised stock options and sold an equivalent number of shares, while also receiving a new grant of stock options.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock for approximately $1.45 million, reducing his direct beneficial ownership.

Corcept Therapeutics Inc. Director Gregg H. Alton was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director David L. Mahoney was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

G. Leonard Baker Jr., a Director and 10% Owner of Corcept Therapeutics Inc., was granted 15,000 stock options exercisable at $72.27 per share.

Joseph K. Belanoff, CEO and Director of Corcept Therapeutics Inc., sold 39,000 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported a series of equity transactions including option exercises, stock sales under a 10b5-1 plan, and new restricted stock awards.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, executed a series of transactions including the exercise of stock options, acquisition of shares through a purchase plan and restricted stock awards, and the sale of common stock, all under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc., has increased his beneficial ownership in the company through a share purchase plan and the grant of restricted stock awards.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition of 1,550 shares through a purchase plan and restricted stock awards, alongside the disposition of 519 shares for tax withholding purposes, increasing his total beneficial ownership to 14,065 shares.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, has filed a Form 4 detailing a series of share transfers to a family trust and the exercise of stock options, reflecting changes in beneficial ownership.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports the disposition and acquisition of company stock via sales and gifts.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a recent SEC filing.

David Mahoney, a director at Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a Form 4 filing with the SEC.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold shares on May 12, 2025, according to a Form 4 filing with the SEC.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed a stock option exercise and sale on May 6, 2025, according to a Form 4 filing.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics common stock on May 1st and 2nd, 2025, according to a Form 4 filing with the SEC.

Corcept Therapeutics CEO Joseph K. Belanoff executed sales of common stock on May 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 1, 2025, according to a Form 4 filing.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock, including shares held directly and indirectly through custodial accounts.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics (CORT) common stock on March 31, 2025, and April 1, 2025, according to a Form 4 filing with the SEC.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 31 and April 1, 2025, according to a Form 4 filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, reports the acquisition and disposal of common stock and stock options on April 1, 2025, according to a Form 4 filing.

Corcept Therapeutics CEO Joseph K. Belanoff sold shares of common stock on March 31, 2025, and April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 24, 2025, according to a recent SEC filing.